A large international research consortium aim in 2009 to send a proposal to National Institute of Health in USA for funding exploring IC2 ability for clinical medical imaging by immunoPET and immunoPAT.
“Diabetes Studies Review”” May issue 2008, highlight some novel noninvasive imaging approaches with.
A grant from JDRF now unable DNA cloning of IC2. The project runs for two years and was initatied in September 2008.
A consortium consisting of University of Copenhagen, MilleGen in Toulouse and Stanford University collaborate on the DNA clone IC2 and create fusion-proteins for optical in vivo imaging.
ImmunoSigns and Antibody-Online will will makek partnership for an international marketing and sale of IC2 in 2011. A contact is under nogotiation.
Lecturing on miniaturized and high-throughput lab-on-a-chip and microfluidic analytical methods for Confex, Denmark.
ImmunoSigns CSO, Carl-Henrik Brogren, consulting TTO, copenhagen on innovative cell technology.
Since 1996, ImmunoSigns – previous CHB-Consult, has given license to R-Biopharm, Darmstadt, Germany, to commercialise a beta-lactoglobulin immunoassay (BLG-ELISA), especially design to measure degraded BLG in infant food formulas, and other food items. The License expired by December 2004. A new license contract on nisin immunoassays (Nisin ELISA) applicable in testing food conserved by this bacteriocin has been […]
ImmunoSigns CSO, Carl-Henrik Brogren, consulting for the French Inserm-Transfer and the French National Research Agency, ANR, promoting the transfer of knowledge and technologies between public laboratories and industrial laboratories to support the development of biotechnologies and their applications. Within the framework of ANR’s Biotechnology programmes, biotechnologies shall be construed broadly so as to encompass not […]
ImmunoSigns CSO, Carl-Henrik Brogren, lecturing on Lab-on-a-Chip technologies and microfluidic analytical methods for Confex, Denmark on June 7, 2007.